Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089283105> ?p ?o ?g. }
- W3089283105 endingPage "1435" @default.
- W3089283105 startingPage "1425" @default.
- W3089283105 abstract "The cardiovascular effects of ertugliflozin, an inhibitor of sodium-glucose cotransporter 2, have not been established.In a multicenter, double-blind trial, we randomly assigned patients with type 2 diabetes and atherosclerotic cardiovascular disease to receive 5 mg or 15 mg of ertugliflozin or placebo once daily. With the data from the two ertugliflozin dose groups pooled for analysis, the primary objective was to show the noninferiority of ertugliflozin to placebo with respect to the primary outcome, major adverse cardiovascular events (a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke). The noninferiority margin was 1.3 (upper boundary of a 95.6% confidence interval for the hazard ratio [ertugliflozin vs. placebo] for major adverse cardiovascular events). The first key secondary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure.A total of 8246 patients underwent randomization and were followed for a mean of 3.5 years. Among 8238 patients who received at least one dose of ertugliflozin or placebo, a major adverse cardiovascular event occurred in 653 of 5493 patients (11.9%) in the ertugliflozin group and in 327 of 2745 patients (11.9%) in the placebo group (hazard ratio, 0.97; 95.6% confidence interval [CI], 0.85 to 1.11; P<0.001 for noninferiority). Death from cardiovascular causes or hospitalization for heart failure occurred in 444 of 5499 patients (8.1%) in the ertugliflozin group and in 250 of 2747 patients (9.1%) in the placebo group (hazard ratio, 0.88; 95.8% CI, 0.75 to 1.03; P = 0.11 for superiority). The hazard ratio for death from cardiovascular causes was 0.92 (95.8% CI, 0.77 to 1.11), and the hazard ratio for death from renal causes, renal replacement therapy, or doubling of the serum creatinine level was 0.81 (95.8% CI, 0.63 to 1.04). Amputations were performed in 54 patients (2.0%) who received the 5-mg dose of ertugliflozin and in 57 patients (2.1%) who received the 15-mg dose, as compared with 45 patients (1.6%) who received placebo.Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular events. (Funded by Merck Sharp & Dohme and Pfizer; VERTIS CV ClinicalTrials.gov number, NCT01986881.)." @default.
- W3089283105 created "2020-10-01" @default.
- W3089283105 creator A5000786302 @default.
- W3089283105 creator A5025169113 @default.
- W3089283105 creator A5026602252 @default.
- W3089283105 creator A5026935251 @default.
- W3089283105 creator A5029467844 @default.
- W3089283105 creator A5033587716 @default.
- W3089283105 creator A5044853663 @default.
- W3089283105 creator A5051174907 @default.
- W3089283105 creator A5055021020 @default.
- W3089283105 creator A5059098934 @default.
- W3089283105 creator A5070855397 @default.
- W3089283105 creator A5071945904 @default.
- W3089283105 creator A5079232498 @default.
- W3089283105 creator A5084634888 @default.
- W3089283105 creator A5090448050 @default.
- W3089283105 date "2020-10-08" @default.
- W3089283105 modified "2023-10-17" @default.
- W3089283105 title "Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes" @default.
- W3089283105 cites W2016471508 @default.
- W3089283105 cites W2060499368 @default.
- W3089283105 cites W2146264128 @default.
- W3089283105 cites W2191191124 @default.
- W3089283105 cites W2412117889 @default.
- W3089283105 cites W2424539745 @default.
- W3089283105 cites W2606281213 @default.
- W3089283105 cites W2626446274 @default.
- W3089283105 cites W2761588741 @default.
- W3089283105 cites W2790570046 @default.
- W3089283105 cites W2890465901 @default.
- W3089283105 cites W2900413769 @default.
- W3089283105 cites W2904387867 @default.
- W3089283105 cites W2939222610 @default.
- W3089283105 doi "https://doi.org/10.1056/nejmoa2004967" @default.
- W3089283105 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32966714" @default.
- W3089283105 hasPublicationYear "2020" @default.
- W3089283105 type Work @default.
- W3089283105 sameAs 3089283105 @default.
- W3089283105 citedByCount "822" @default.
- W3089283105 countsByYear W30892831052020 @default.
- W3089283105 countsByYear W30892831052021 @default.
- W3089283105 countsByYear W30892831052022 @default.
- W3089283105 countsByYear W30892831052023 @default.
- W3089283105 crossrefType "journal-article" @default.
- W3089283105 hasAuthorship W3089283105A5000786302 @default.
- W3089283105 hasAuthorship W3089283105A5025169113 @default.
- W3089283105 hasAuthorship W3089283105A5026602252 @default.
- W3089283105 hasAuthorship W3089283105A5026935251 @default.
- W3089283105 hasAuthorship W3089283105A5029467844 @default.
- W3089283105 hasAuthorship W3089283105A5033587716 @default.
- W3089283105 hasAuthorship W3089283105A5044853663 @default.
- W3089283105 hasAuthorship W3089283105A5051174907 @default.
- W3089283105 hasAuthorship W3089283105A5055021020 @default.
- W3089283105 hasAuthorship W3089283105A5059098934 @default.
- W3089283105 hasAuthorship W3089283105A5070855397 @default.
- W3089283105 hasAuthorship W3089283105A5071945904 @default.
- W3089283105 hasAuthorship W3089283105A5079232498 @default.
- W3089283105 hasAuthorship W3089283105A5084634888 @default.
- W3089283105 hasAuthorship W3089283105A5090448050 @default.
- W3089283105 hasBestOaLocation W30892831051 @default.
- W3089283105 hasConcept C126322002 @default.
- W3089283105 hasConcept C127413603 @default.
- W3089283105 hasConcept C134018914 @default.
- W3089283105 hasConcept C141071460 @default.
- W3089283105 hasConcept C142724271 @default.
- W3089283105 hasConcept C164705383 @default.
- W3089283105 hasConcept C197934379 @default.
- W3089283105 hasConcept C204787440 @default.
- W3089283105 hasConcept C207103383 @default.
- W3089283105 hasConcept C27081682 @default.
- W3089283105 hasConcept C2777180221 @default.
- W3089283105 hasConcept C2777422806 @default.
- W3089283105 hasConcept C2778198053 @default.
- W3089283105 hasConcept C2780645631 @default.
- W3089283105 hasConcept C44249647 @default.
- W3089283105 hasConcept C500558357 @default.
- W3089283105 hasConcept C555293320 @default.
- W3089283105 hasConcept C71924100 @default.
- W3089283105 hasConcept C78519656 @default.
- W3089283105 hasConceptScore W3089283105C126322002 @default.
- W3089283105 hasConceptScore W3089283105C127413603 @default.
- W3089283105 hasConceptScore W3089283105C134018914 @default.
- W3089283105 hasConceptScore W3089283105C141071460 @default.
- W3089283105 hasConceptScore W3089283105C142724271 @default.
- W3089283105 hasConceptScore W3089283105C164705383 @default.
- W3089283105 hasConceptScore W3089283105C197934379 @default.
- W3089283105 hasConceptScore W3089283105C204787440 @default.
- W3089283105 hasConceptScore W3089283105C207103383 @default.
- W3089283105 hasConceptScore W3089283105C27081682 @default.
- W3089283105 hasConceptScore W3089283105C2777180221 @default.
- W3089283105 hasConceptScore W3089283105C2777422806 @default.
- W3089283105 hasConceptScore W3089283105C2778198053 @default.
- W3089283105 hasConceptScore W3089283105C2780645631 @default.
- W3089283105 hasConceptScore W3089283105C44249647 @default.
- W3089283105 hasConceptScore W3089283105C500558357 @default.
- W3089283105 hasConceptScore W3089283105C555293320 @default.
- W3089283105 hasConceptScore W3089283105C71924100 @default.